8-K: Curis Reports Q1 2026 Results, Advances Emavusertib Trials

Curis, Inc. announced its first-quarter 2026 business update and financial results, highlighting progress in emavusertib clinical trials for lymphoma and leukemia, alongside a net loss of $24.2 million.

Summary

• Curis, Inc. reported its financial results for the first quarter ended March 31, 2026.
• The company announced a net loss of $24.2 million, or $1.25 per share, compared to a net loss of $10.6 million, or $1.25 per share, in the first quarter of 2025.
• Revenues were nil for the quarter ended March 31, 2026, due to the prior sale of Erivedge royalties, compared to $2.4 million in the same period of 2025.
• Research and development expenses decreased to $6.4 million from $8.5 million.
• General and administrative expenses increased to $5.1 million from $4.0 million, largely due to financing costs.
• Other expense, net significantly increased to $12.7 million from $0.5 million, primarily due to changes in the fair value of warrant liabilities.
• As of March 31, 2026, Curis had $15.0 million in cash and cash equivalents.
• The company expects its current cash and anticipated proceeds from warrant exercises to fund operations into the second half of 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, with significant clinical progress and strategic financing, but offset by continued substantial net losses and a critical need for future funding.

Positives

• Patient enrollment is ongoing for the TakeAim Lymphoma Phase 1/2 trial of emavusertib in combination with ibrutinib for Relapsed or Refractory Primary CNS Lymphoma (PCNSL).
• The ongoing Phase 1/2 study is intended to support accelerated approval filings for emavusertib in PCNSL in the US and Europe.
• Emavusertib has received Orphan Drug Designation from both the FDA and EMA for PCNSL.
• The TakeAim CLL Phase 2 clinical trial of emavusertib in combination with zanubrutinib for Chronic Lymphocytic Leukemia (CLL) has been initiated.
• The combination of emavusertib with a BTKi aims to achieve dual blockade of NF-kB, potentially leading to deeper responses, complete remission, or undetectable minimal residual disease (MRD) in CLL and NHL.
• Initial clinical data in gastric and esophageal cancer, presented at ASCO GI, showed a manageable toxicity profile and encouraging preliminary results.
• Curis expects to announce dosing of the initial 5 patients in the TakeAim CLL study by mid-2026, with data expected in December 2026.
• Updated emavusertib clinical data from the TakeAim Lymphoma study is expected in the first half of 2027.

Negatives

• The company reported a net loss of $24.2 million for the first quarter of 2026.
• There were no revenues for the quarter ended March 31, 2026, due to the sale of Erivedge royalties in the prior year.
• General and administrative expenses increased due to financing costs associated with the January 2026 PIPE Financing.
• Other expense, net, increased significantly due to changes in the fair value of warrant liabilities.
• As of March 31, 2026, Curis had $15.0 million in cash and cash equivalents, which is insufficient to support operations for the next 12 months without additional funding.
• The company will require substantial additional funding to continue development and operations.

Risks

• Curis may experience adverse results, delays, and/or failures in its drug development programs.
• Drug candidates may cause unexpected toxicities or fail to demonstrate sufficient safety and efficacy in clinical studies.
• Favorable results from preclinical and early clinical trials may not be replicated in later trials.
• Delays in the development of emavusertib could have a material adverse effect on the business.
• Curis requires substantial additional capital to fund its business, and failure to obtain sufficient funding could force delays or elimination of development programs.
• Curis faces substantial competition in the biotechnology sector.
• Potential adverse decisions from regulatory authorities like the FDA and EMA could impact development.
• Curis may not obtain or maintain necessary patent protection and could face patent litigation.

Future Outlook

Curis anticipates its current cash position and anticipated proceeds from warrant exercises will fund operations into the second half of 2027. The company expects to announce dosing of the initial 5 patients in the TakeAim CLL study by mid-2026, with data expected in December 2026, and updated emavusertib clinical data from the TakeAim Lymphoma study in the first half of 2027.

Management Comments

• Emavusertib has been granted orphan drug designation by both FDA and EMA in PCNSL.
• The goal of combining emavusertib with a BTKi is to enable a dual blockade of NF-kB, a key driver of disease in CLL and NHL, by inhibiting both the TLR and BCR pathways.
• Previous clinical studies have shown that adding emavusertib, which blocks the TLR pathway, to a BTKi regimen can enable patients with NHL to achieve deeper responses, including complete remission or undetectable minimal residual disease (MRD) and the potential for time-limited treatment, outcomes which represent the potential for a paradigm shift in the management of CLL.
• Curis expects to announce the dosing of the initial 5 patients in the TakeAim CLL combination study with zanubrutinib by mid-2026, with data expected in December 2026.
• The Company expects updated emavusertib clinical data from the TakeAim Lymphoma combination study with ibrutinib in patients with R/R PCNSL in the first half of 2027.

Industry Context

StockSavvy.ai notes that Curis's focus on emavusertib, an IRAK4 and FLT3 inhibitor, aligns with the broader trend in oncology of developing targeted therapies and combination treatments to achieve deeper patient responses and potentially overcome resistance mechanisms seen with standard of care agents like BTK inhibitors.

Comparison to Industry Standards

• The development of emavusertib in combination with BTK inhibitors for CLL and NHL aims to achieve complete remissions and undetectable minimal residual disease (MRD), which are considered higher benchmarks for treatment success compared to the partial responses often seen with BTK inhibitors alone.
• The pursuit of accelerated approval for emavusertib in PCNSL, supported by Orphan Drug Designation, is a common strategy for rare diseases where significant unmet medical need exists, mirroring approaches taken by other companies in niche oncology indications.

Stakeholder Impact

• Shareholders: The company's reliance on future capital raises and the potential for dilution from warrant exercises could impact shareholder value. Positive clinical trial updates may drive stock price appreciation.
• Employees: Continued development of drug candidates provides job security and potential for future growth within the company.
• Creditors: The company's cash position and need for future funding may impact its ability to meet short-term obligations if additional capital is not secured.

Next Steps

• Announce dosing of the initial 5 patients in the TakeAim CLL combination study with zanubrutinib by mid-2026.
• Present data from the TakeAim CLL combination study in December 2026.
• Provide updated emavusertib clinical data from the TakeAim Lymphoma combination study in the first half of 2027.
• Support filings for accelerated approval of emavusertib in PCNSL in the US and Europe based on ongoing Phase 1/2 study.

Key Dates

Recommendation

The company shows promising clinical development for emavusertib and has secured some financing, but the significant net losses and ongoing need for substantial future capital present considerable risk. While clinical progress is positive, the path to commercialization is long and uncertain, warranting a hold recommendation until further de-risking events occur.

Keywords

Curis, emavusertib, biotechnology, oncology, clinical trials, lymphoma, leukemia, financial results